The NASH drug, PLN-1474, is a small molecule inhibitor of integrin αVβ Pliant thinks can reduce the growth of fibrotic tissue in the liver.
The creation of the latest outpost of the BRIDGE model sees Evotec team up with Integra Holdings and Yissum to help researchers at Hebrew University.
Nearly 80% of clinical trials fail to meet their activation timelines. But why does the start-up process fail us this often? Read the article to learn
Rapt Therapeutics filed to raise up to $75 million in its IPO after postponing an earlier attempt to raise $86 million in August.
Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.
A clinical trial is a measurement system, but too often, we fail to calibrate the most significant of measurement instruments: trial participants.
The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.
Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.
Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.
Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.
The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.
In a classic plot line for biotechs, Aerpio is seeking a “strategic review” for its business and assets after being hit by a trial failure.
